Serum IL-6 Levels In Patients Research Articles

Effects of metformin on blood and urine pro-inflammatory mediators in patients with type 2 diabetes

BackgroundMetformin has been used for the treatment of type 2 diabetes by suppressing hepatic gluconeogenesis. It has been shown that the subclinical inflammatory responses play important roles in the pathogenesis of type 2 diabetes. In the present study, we determined the effects of metformin on the levels of pro-inflammatory cytokines (i.e., IL-6, TNF-α, and MCP-1) and anti-inflammatory mediator IL-10 in blood and urine of patients with type 2 diabetes. There were 210 patients with type 2 diabetes, which were randomized into metformin (n = 112) and non-metformin (gliclazide, acarbose, and repaglinide, n = 98) groups. The levels of cytokines were measured by the ELISA.ResultsWe found that metformin reduced the levels of IL-6 in blood and MCP-1 in urine, but increased IL-10 levels in blood of patients with type 2 diabetes. There were no significant differences of TNF-α between metformin and non-metformin groups. Furthermore, compared to individual drug treatment, metformin significantly reduced the levels of serum IL-6 and TNF-α, as well as urine MCP-1. When the patients were stratified based on the durations and doses of metformin, we found that there was only change (i.e., increase) in serum IL-10 levels in patients with metformin for more than 1 year compared to treatment for less than 1 year. Metformin (1.5 g) treatment reduced the urinary levels of MCP-1 as compared with dose of 1.0 g in patients with type 2 diabetes.ConclusionMetformin reduces inflammatory responses without influence on renal function in type 2 diabetic patients.

Interleukin-21 plays a critical role in the pathogenesis and severity of type I autoimmune hepatitis.

Background and aimsRecently, the number of follicular helper T (Tfh) cells expressing interleukin (IL)-21 was found to increase in peripheral blood of human and murine models of autoimmune hepatitis (AIH). IL-21, the most recently discovered member of the type-I cytokine family, exerts various effects on the immune system, including B cell activation, plasma cell differentiation, and immunoglobulin production. We aimed to assess the relationship of serum IL-21 levels in patients with type I AIH with clinical and laboratory parameters and histology.MethodsNinety-two Japanese patients with liver disease (22 AIH, 20 primary biliary cholangitis, 19 drug-induced liver injury, 8 acute hepatitis B, 8 chronic hepatitis C, 10 non-alcoholic steatohepatitis, 5 viral hepatitis) and 10 healthy volunteers were recruited. Serum IL-21 levels were detected by enzyme-linked immunosorbent assay. Real-time polymerase chain reaction measured mRNA levels of Bcl-6, IL-21, and CXCR5 (Tfh-related factors) in peripheral mononuclear cells.ResultsMean age at diagnosis of AIH was 58.6 years, male-to-female ratio was 4:18, 18.2 % of participants had cirrhosis, and 22.7 % had severe disease. IL-21 levels were significantly increased in the serum of patients with AIH compared to those with other liver diseases and controls (p < 0.0001). Particularly, serum IL-21 levels were significantly increased in severe AIH cases compared to non-severe cases (p < 0.05). Serum IL-21 levels correlated positively with total serum bilirubin levels (r = 0.46, p < 0.05), grading of necroinflammatory activity (r = 0.68, p < 0.005) and negatively with serum albumin levels in patients with AIH (r = −0.49, p < 0.05). In patients with biochemical remission of AIH, serum IL-21 levels remained elevated and correlated positively with serum IgG levels (r = 0.84, p < 0.01). Expression of Tfh-related factors, such as Bcl-6 and IL-21, in peripheral blood mononuclear cells of patients with AIH was significantly higher than that in healthy volunteers.ConclusionsIL-21 may play an important role in the pathogenesis and severity of AIH, and may present a promising target for AIH therapy.Electronic supplementary materialThe online version of this article (doi:10.1186/s40064-016-2512-y) contains supplementary material, which is available to authorized users.

Interleukin-6 gene polymorphisms in Egyptian children with febrile seizures: a case-control study.

BackgroundFebrile seizures are the most common form of childhood seizures. Among pro-inflammatory cytokines, interleukin-6 is the key acute-phase cytokine. To date, only a few studies concerned the association of interleukin-6 gene polymorphisms with febrile seizures.In this study, we aimed to investigate 3 cytokine single-nucleotide polymorphisms situated at positions –174 (G/C), –572 (G/C), and –597 (G/A) in the promoter region of the interleukin-6 gene for the first time in Egyptian children with febrile seizures.MethodsThis was a case–control study included 100 patients with febrile seizure, and matched with age, gender, ethnicity 100 healthy control subjects.Interleukin-6 –174 (G/C), −572 (G/C), and −597 (G/A) polymorphisms were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), while the serum IL6 levels were measured by ELISA method.ResultsCompared to the controls subjects, the frequency of the −174 GG and −597 GG IL6 genotypes were observed to be increased in children with febrile seizures (OR: 4.17; 95 % CI: 1.86–9.49; P <0.01 and OR: 1.96; 95 % CI: 1.06–3.63;P <0.05, respectively). We found a significant positive association between the −597 GG genotype and susceptibility to complex febrile seizures as did the G allele at the same position (OR: 4.2; 95 % CI: 1.4–13.3 for the GG genotype; P <0.01) and (OR: 2.89; 95 % CI: 1.1–7.7 for the G allele; P <0.05 respectively). Our data revealed no association between IL6- genotypes and serum IL6 levels in patients with febrile seizures (P > 0.05).ConclusionIn conclusion, our data brought a novel observation that the presence of a G allele or GG genotype at the −174 and the GG genotype at the −597 positions of the promoter region of the interleukin-6 gene constitute risk factors for developing febrile seizures in Egyptian children. Moreover, we observed a significant positive association between the IL6 –597 GG genotype and susceptibility to complex febrile seizures as did the G allele at the same position. However, we found no association between IL6- genotypes and serum IL6 levels in patients with febrile seizures.

Decreased interleukin-21 expression in skin and blood in advanced mycosis fungoides.

Interleukin (IL)-21 is regarded as a potent antitumor agent, which increases the cytotoxicity of both natural killer (NK) and CD8(+) T cells. In this study, we investigated the role of IL-21 in mycosis fungoides (MF). IL-21 mRNA expression levels in patch and plaque MF were significantly higher than those in normal skin. IL-21 mRNA expression levels in tumor MF were significantly decreased compared with those in patch and plaque MF. Interestingly, mRNA expression levels of IL-21 in MF lesional skin significantly correlated with those of T-helper type-1 cytokines/chemokines such as CXCL10, CXCL11 and γ-interferon. Immunohistochemistry showed that IL-21 was expressed by keratinocytes in patch and plaque MF. Furthermore, serum IL-21 levels in patients with tumor MF were significantly lower than those of healthy controls and plaque MF. Thus, IL-21 expression was significantly downregulated in skin and blood of patients with tumor MF, which may contribute to progression of MF. Our study suggests that recombinant IL-21 would be a promising therapy for MF.

CHANGES IN SERUM LEVELS OF IL-6 IN THE EARLY POSTOPERATIVE PERIOD AFTER PREEMPTIVE ANALGESIA WITH NIMESULIDE, METAMIZOLE SODIUM AND PLACEBO IN REMOVAL OF IMPACTED MANDIBULAR THIRD MOLARS

Objective: The objective of this study is to determine the change in IL-6 serum levels in patients undergoing preemptive analgesia and surgical removal of an impacted mandibular third molar. Study Design: This is a prospective, double-blind, placebo-controlled study in 80 patients who had an atypical extraction of an impacted mandibular third molar. Results: After surgical removal of impacted mandibular third molars, elevated levels of IL-6 in the early postoperative period were found, and the highest level was 14 pg/ml. Conclusion: Postoperative IL-6 levels rise regardless of the medication used for preemptive analgesia. In the group treated with nimesulide, a trend to reducing IL-6 levels was observed, but further study in a larger number of patients is needed.

Predictors of positive pain outcome from brace wearing in PFJOA

s / Osteoarthritis and Cartilage 23 (2015) A82eA416 A391 characteristics were observed between the exercise therapy group and the control group. The JKOM score (p<0.001 and p<0.001, respectively) and VAS score (p<0.001 and p<0.001, respectively) at 12 weeks of the patients with both the exercise therapy and control groups were significantly reduced in comparison to those at baseline. The hs-CRP levels remained unchanged in patients with both groups (p1⁄40.267 and p1⁄40.137, respectively). The sIL-6 levels of the patients in the exercise therapy group were significantly decreased (p1⁄40.021) in comparison to those of the patients at baseline, but sIL-6 levels of the patients in the control group were not. Conclusions: The serum IL-6 levels in patients with OA were significantly reduced by the exercise therapy, while sIL-6 levels were unchanged by NSAID, suggesting that exercise therapy may exert antiinflammatory effects in knee OA. 650 THE EFFECTS OF KINESIO TAPING ON PAIN, MUSCLE STRENGHT AND FUNCTION IN SUBJECTS WITH KNEE OSTEOARHRITIS: PILOT STUDY E. Kaya Mutlu, R. Mustafaoglu, A. Razak Ozdincler. Istanbul Univ., Faculty of Hlth. Sci., Div. of Physiotherapy and Rehabilitation, Istanbul,

The effects of kinesio taping on pain, muscle strenght and function in subjects with knee osteoarhritis: pilot study

s / Osteoarthritis and Cartilage 23 (2015) A82eA416 A391 characteristics were observed between the exercise therapy group and the control group. The JKOM score (p<0.001 and p<0.001, respectively) and VAS score (p<0.001 and p<0.001, respectively) at 12 weeks of the patients with both the exercise therapy and control groups were significantly reduced in comparison to those at baseline. The hs-CRP levels remained unchanged in patients with both groups (p1⁄40.267 and p1⁄40.137, respectively). The sIL-6 levels of the patients in the exercise therapy group were significantly decreased (p1⁄40.021) in comparison to those of the patients at baseline, but sIL-6 levels of the patients in the control group were not. Conclusions: The serum IL-6 levels in patients with OA were significantly reduced by the exercise therapy, while sIL-6 levels were unchanged by NSAID, suggesting that exercise therapy may exert antiinflammatory effects in knee OA. 650 THE EFFECTS OF KINESIO TAPING ON PAIN, MUSCLE STRENGHT AND FUNCTION IN SUBJECTS WITH KNEE OSTEOARHRITIS: PILOT STUDY E. Kaya Mutlu, R. Mustafaoglu, A. Razak Ozdincler. Istanbul Univ., Faculty of Hlth. Sci., Div. of Physiotherapy and Rehabilitation, Istanbul,

Increased circulating follicular helper T cells and activated B cells correlate with disease severity in patients with psoriasis.

Follicular Helper T (TFH) Cells are a population of recently discovered CD4(+) T cells involved in autoimmune diseases. However, the contribution of TFH cells in patients with psoriasis remains unknown. We aimed to investigate the levels of TFH cells, B cells and their clinical relevance in patients with psoriasis. Using multi-colour flow cytometry, we detected different subsets of TFH cells and B cells in the peripheral blood of 27 patients with psoriasis and 13 healthy donors. Serum IL-21 levels were measured by ELISA. The relationship between the levels of TFH cells, IL-21, B cells and disease severity were analysed. Compared with healthy donors, higher levels of circulating CD3(+) CD4(+) CXCR5(+) cells, CD3(+) CD4(+) CXCR5(+) ICOS(+), CD3(+) CD4(+) CXCR5(+) PD-1(+), CD3(+) CD4(+) CXCR5(+) ICOS(+) PD-1(+) TFH cells and CD19(+) IgD(+) CD27(-) naive B, CD19(+) CD86(+) activated B, but lower levels of CD19(+) IgD(+) CD27(+) preswitch and CD19(+) IgD(-) CD27(+) postswitch memory B cells, were observed in patients with psoriasis. In addition, serum IL-21 levels in patients with psoriasis were significantly higher than those in healthy donors, and showed to be positively correlated with the levels of different subsets of TFH cells, and the level of CD19(+) CD86(+) B cells was also correlated with TFH cells and IL-21 levels. Furthermore, a significant correlation was found between the levels of CD3(+) CD4(+) CXCR5(+) ICOS(+) TFH cells, CD3(+) CD4(+) CXCR5(+) ICOS(+) PD-1(+) TFH cells, CD19(+) CD86(+) B cells and IL-21 with Psoriasis Area and Severity Index scores. The levels of TFH cells and activated B cells were increased in the peripheral blood of patients with psoriasis, and positively correlated with disease severity. These results suggest that TFH cells and activated B cells may play a role in the pathogenesis of psoriasis.

The correlations of serum interleukin-6 (il-6) levels and serum soluble il-6 receptor levels with disease activity in systemic juvenile idiopathic arthritis patients with and without tocilizumab treatment

Results Forty-two SJIA patients, 131 blood samplings were included in this study. Seventeen patients (40%) were treated with tocilizumab during the study. Serum IL-6 levels in patients without tocilizumab treatment significantly elevated in active disease with systemic features and arthritis [median (IQR) = 101.8 (303.2) pg/mL] when compared to active disease with only arthritis [median (IQR) = 4.5 (23) pg/mL], and remission on medication [median (IQR) = 1.5 (0.55) pg/mL], whereas serum IL-6 levels in patients with tocilizumab treatment were not different between groups but there were significantly different when compared to healthy children (p < 0.05). In addition, the correlation between serum IL-6 levels and JADAS-71 in patients without tocilizumab treatment (r = 0.71, p < 0.001) was stronger than patients with tocilizumab treatment (r = 0.42, p = 0.01). Serum sIL-6R levels in SJIA patients with and without tocilizumab treatment were significantly higher when compared to healthy children (p < 0.05). Interestingly, in patients with tocilizumab treatment, serum sIL-6R levels were extremely higher [median (IQR) = 1,110.3 (840.2) ng/mL] than patients without tocilizumab treatment [median (IQR) = 94.2 (82.7) ng/mL]. Conclusion The correlation between serum IL-6 levels and disease activity in patients without tocilizumab treatment was stronger than patients with tocilizumab treatment. In addition, serum sIL-6R levels in patients with tocilizumab treatment were extremely higher than patients without tocilizumab treatment.

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer.

BackgroundWe previously reported the role of IL-6 in a murine model of cancer cachexia and currently documented a patient in whom tocilizumab, anti-IL-6 receptor antibody, dramatically improved cachexia induced by IL-6 over-expressing lung cancer. Despite this potential to alleviate cancer cachexia, tocilizumab has not been approved for this clinical use. Therefore, preceding our planned clinical trial of tocilizumab, we designed the two studies described here to evaluate the levels of IL-6 in patients with lung cancer and the effect of tocilizumab in a murine model of human cancer cachexia.MethodsFirst, we measured serum IL-6 levels in patients with lung cancer and analyzed its association with cachexia and survival. Next, we examined the effect of a rodent analog of tocilizumab (MR16-1) in the experimental cachexia model.ResultsSerum IL-6 levels were higher in patients with cachexia than those without cachexia. In patients with chemotherapy-resistant lung cancer, a high IL-6 serum level correlated strongly with survival, and the cut-off level for affecting their prognosis was 21 pg/mL. Meanwhile, transplantation of IL-6-expressing Lewis Lung Carcinoma cells caused cachexia in mice, which then received either MR16-1 or 0.9% saline. Tumor growth was similar in both groups; however, the MR16-1 group lost less weight, maintained better food and water intake and had milder cachectic features in blood. MR16-1 also prolonged the survival of LLC-IL6 transplanted mice (36.6 vs. 28.5 days, p = 0.016).ConclusionOur clinical and experimental studies revealed that serum IL-6 is a surrogate marker for evaluating cachexia and the prognosis of patients with chemotherapy resistant metastatic lung cancer and that tocilizumab has the potential of improving prognosis and ameliorating the cachexia that so devastates their quality of life. This outcome greatly encourages our clinical trials to evaluate the safety and efficacy of tocilizumab treatment for patients with increased serum IL-6.

Serum IL-18 as a potential specific marker for differentiating systemic juvenile idiopathic arthritis from incomplete Kawasaki disease.

Clinical features and laboratory parameters in patients with incomplete Kawasaki disease (KD) and systemic juvenile idiopathic arthritis (s-JIA) tend to overlap. Furthermore, there have been no definite biomarkers for these diseases. This situation makes the clinical diagnosis of these patients difficult. In this study, we aimed to measure serum interleukin (IL)-18 and IL-6 levels in patients with s-JIA who were initially diagnosed with incomplete KD and compare these data with those in patients with complete KD and arthritis. Serum IL-18 levels in patients with s-JIA were significantly elevated compared with those in patients with KD and arthritis. Pediatricians should be aware that the presentation of s-JIA can mimic incomplete KD. Because the clinical features overlap, a high index of suspicion is warranted. The measurement of serum IL-18 may be useful for differentiating s-JIA from KD.

FRI0424 Role of IL-10 Gene Polymorphism and C1q Antibodies in Clinicopathological Presentations and Treatment Response in Lupus Nephritis Patients

BackgroundDefining an early and reliable and non invasive biomarker of kidney involvement in SLE is highly desirable. Anti-C1q auto antibodies have been proposed as a useful marker in SLE since...

Serum interleukin-17 levels and rheumatoid arthritis patients with bone and joint damage

Objective To observe the correlation between serum interleukin (IL)-17 levels with bone and joint damage in rheumatoid arthritis (RA) patients and the possible mechanism.Methods Fifty-five cases of RA in our hospital were selected as the observation group during the period from October 2010 to June 2013,and 55 healthy volunteers were selected as the control group simultaneously.The serum IL-17 and anti-cyclic citrullinated peptide antibody (anti-CCP) levels were detected by double antibody sandwich enzyme linked immunosorbent assay (ELISA).The serum IL-17 levels in RA patients with different stages of X-ray were compared.The relationship between serum IL-17 levels with active phase,rheumatoid factor and morning stiffness was observed.Results The serum IL-17 levels [(308.42 ±76.14) ng/L] and anti-CCP levels [(1 325.3 ±234.1) AU/ml] in the observation group were significantly higher than those of the control group (P ＜0.05).There was significant difference in the serum IL-17 levels among different stages of X-ray.The higher the stages of X-ray,the higher the levels of serum IL-17 [the serum IL-17 levels at stage Ⅰ,Ⅱand Ⅲ:[(208.23 ±67.41),(322.62 ±78.35),(452.81 ±88.32) ng/L,P＜0.05].The serum IL-17 levels at the active phase [(342.61 ± 101.41) ng/L] were significantly higher than those of the patients at the non-active period [(228.61 ± 101.54) ng/L].The serum IL-17 levels in patients positive for serum rheumatoid factor [(318.74 ±98.42) ng/L] were higher than those of the patients negative for serum rheumatoid factor-negative [(220.56 ± 99.62) ng/L].The serum IL-17 levels were significantly higher in patients with long duration of morning stiffness [(356.27 ± 88.74) ng/L] than those in patients with a short duration of morning stiffness [(201.38 ± 78.43) ng/L,P ＜ 0.05].Conclusion Serum IL-17 plays an important role in the development of RA.Patients with severe bone and joint damage have high serum IL-17 levels. Key words: Interleukin-17; Rheumatoid arthritis; Bone and joint damage

Serum IL-21 levels associated with chronic hepatitis B and hepatitis B-related liver failure

The aim of the present study was to investigate the role of interleukin (IL)-21 in chronic hepatitis B virus (HBV) infection. IL-21 stimulates T and B cell responses and plays a role in the control of chronic viral infections. Serum IL-21 levels were measured by enzyme immunoassay in 109 patients with chronic HBV infection at various clinical stages, as well as in 19 healthy controls (HCs). The proportion of T cells producing IL-21 in the peripheral blood was assessed by intracellular cytokine staining and flow cytometry. Mean serum IL-21 levels in patients with chronic hepatitis B (CHB) and the HCs were 303.54±152.77 pg/ml and 68.24±9.06 pg/ml, respectively (P=0.003). In addition, the mean serum IL-21 level in patients with hepatitis B-related acute-on-chronic liver failure (HB-ACLF) was 455.38±412.38 pg/ml, which exhibited a statistically significant difference when compared with the HCs (P=0.000). Serum IL-21 levels were highest in the patients with HB-ACLF (455.38±412.38 pg/ml) and exhibited a significant difference when compared with the CHB patients (P=0.04). The mean serum IL-21 levels in patients with cirrhosis also increased, but there was no statistically significant difference when compared with the HCs (P=0.82). The frequency of IL-21+CD4+ cells also increased compared with the HCs and correlated with the number and percentage of lymphocytes in the peripheral blood. Serum IL-21 levels increased in CHB and HB-ACLF patients. Relatively low serum IL-21 levels in CHB may have a causal role in the persistence of HBV infection. Higher serum levels in HB-ACLF may activate T and B cells to eliminate the virus or injure the liver via the release of inflammatory cytokines.

Serum interleukin 17 levels in patients with Crohn's disease: real life data.

The aim of this study was to investigate serum IL17 levels in patients with Crohn's disease (CD) and to investigate the relationship between serum IL17 levels with disease activity. Methods. Fifty patients with CD and sex- and age-matched 40 healthy controls were included in the study. The serum IL17 levels, complete blood count, blood chemistry, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels were measured, and Crohn's disease activity was calculated using Crohn's disease activity index (CDAI). Results. The mean serum IL17 level of CD patients did not differ from those of healthy controls (P > 0.05). There was no difference between the mean serum IL levels of active CD patients and of quiescent CD patients (P > 0.05). However, the mean IL17 level of active patients was lower than of control subjects (P = 0.02). Serum IL17 was not correlated with inflammatory markers (ESR, CRP, white blood count, platelet count, and albumin) and CDAI. Conclusions. Peripheral blood serum IL17 levels of CD patients were not higher than of healthy controls, and also, serum IL17 level was not correlated with clinical disease activity. Peripheral IL17 measurement is not a useful tool for detecting and monitoring Crohn's disease which is understood to have complex etiopathogenesis.

Change of C/A at the SNP -592 of human IL-10 gene increase serum IL-10 levels in patients with cervical lesions and cervical cancer

Event Abstract Back to Event Change of C/A at the SNP −592 of human IL-10 gene increase serum IL-10 levels in patients with cervical lesions and cervical cancer KIRVIS TORRES-POVEDA1, MARGARITA BAHENA-ROMÁN1, ALFREDO LAGUNAS-MARTÍNEZ1, KARINA DELGADO-ROMERO2, DAVID CANTÚ3, ALEJANDRO GARCÍA-CARRANCÁ3 and VICENTE MADRID-MARINA1* 1 INSTITUTO NACIONAL DE SALUD PUBLICA MEXICO, CHRONIC INFECTIONS AND CANCER DIVISION, Mexico 2 HEALTH SERVICES OF STATE OF MORELOS, CAPASAM, Mexico 3 INSTITUTO NACIONAL DE CANCEROLOGÍA MEXICO, Mexico An immunosuppressive state had been identified in women with human papillomavirus (HPV) persistent infection, characterized by high levels of interleukin (IL)-10 at cervix level. We have demonstrated that the -592 SNP in IL-10 gene promoter is associated with increased risk of cervical lesions (CL) and cervical cancer (CC). We analyzed whether exist significative differences of serum IL-10 protein between CL and CC cases and HPV negatives controls. Additionally, whether exchange in this SNP results in increased IL-10 gene promoter activity in HPV transformed cells. Using a cross-sectional design, peripheral blood samples of CL patients (n=204), with CC (n=80) and without CL HPV positives (n=66) and HPV negatives (n=100) were used to evaluate seric concentrations of IL-10 by ELISA. Transient transfection assay was performed in C33 and HeLa cells with two luciferase constructs containing the IL-10 promoter (C allele or A allele) (Figure 1). The serum IL-10 protein, were significantly higher in CL and CC cases (p<0.01), being higher in patients carrying the risk allele A (Figure 2). The mean levels of IL-10 increased in consecutive clinical stages of the CC. The C to A nucleotide exchange results in increased IL-10 gene promoter activity in C33 an HPV transformed cell line. In conclusion, we demonstrated that the C to A nucleotide exchange in this SNP results in increased IL-10 gene promoter activity in HPV transformed cells, supporting its role as an activator element and that be associated with the expression regulation of IL-10 at systemic level, which was progressively higher in CL and CC cases. Figure 1 Figure 2 References Torres-Poveda K, Burguete-García AI, Cruz M, Martínez-Nava GA, Bahena-Román M, Ortíz-Flores E, Ramírez-González A, López-Estrada G, Delgado-Romero K and Madrid-Marina V. The SNP at -592 of Human IL-10 Gene is associated with serum IL-10 levels and Increased Risk for Human Papillomavirus Cervical Lesion Development. Infectious Agents and Cancer 2012; 7(1):32-40. Keywords: Interleukin-10, SNP, Cervical lesion, Cervical Intraepithelial Neoplasia, Serum levels IL-10 Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Immune receptors and signaling Citation: TORRES-POVEDA K, BAHENA-ROMÁN M, LAGUNAS-MARTÍNEZ A, DELGADO-ROMERO K, CANTÚ D, GARCÍA-CARRANCÁ A and MADRID-MARINA V (2013). Change of C/A at the SNP −592 of human IL-10 gene increase serum IL-10 levels in patients with cervical lesions and cervical cancer. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00430 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 10 Apr 2013; Published Online: 22 Aug 2013. * Correspondence: Dr. VICENTE MADRID-MARINA, INSTITUTO NACIONAL DE SALUD PUBLICA MEXICO, CHRONIC INFECTIONS AND CANCER DIVISION, Cuernavaca, MORELOS, 62100, Mexico, vmarina@insp.mx Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers KIRVIS TORRES-POVEDA MARGARITA BAHENA-ROMÁN ALFREDO LAGUNAS-MARTÍNEZ KARINA DELGADO-ROMERO DAVID CANTÚ ALEJANDRO GARCÍA-CARRANCÁ VICENTE MADRID-MARINA Google KIRVIS TORRES-POVEDA MARGARITA BAHENA-ROMÁN ALFREDO LAGUNAS-MARTÍNEZ KARINA DELGADO-ROMERO DAVID CANTÚ ALEJANDRO GARCÍA-CARRANCÁ VICENTE MADRID-MARINA Google Scholar KIRVIS TORRES-POVEDA MARGARITA BAHENA-ROMÁN ALFREDO LAGUNAS-MARTÍNEZ KARINA DELGADO-ROMERO DAVID CANTÚ ALEJANDRO GARCÍA-CARRANCÁ VICENTE MADRID-MARINA PubMed KIRVIS TORRES-POVEDA MARGARITA BAHENA-ROMÁN ALFREDO LAGUNAS-MARTÍNEZ KARINA DELGADO-ROMERO DAVID CANTÚ ALEJANDRO GARCÍA-CARRANCÁ VICENTE MADRID-MARINA Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.

Functional interleukin-17 receptor A are present in the thyroid gland in intractable Graves disease

Th17 lymphocytes and its main cytokine, IL-17, play an important role in autoimmune thyroid diseases, such as intractable Graves disease (GD). IL-17 signals are transmitted through its receptor, IL-17RA. The intrathyroid expression of IL-17RA in intractable GD is not understood. In this study, ELISA was used to measure serum IL-17 levels in patients with untreated GD, intractable GD or GD in remission and healthy controls. Real-time PCR, flow cytometry and immunofluorescence staining evaluated IL-17RA mRNA and protein expression in thyrocytes. IL-6, chemokine ligand 10 (CXCL10) and intercellular adhesion molecule (ICAM)-1 expression was measured in IL-17-stimulated thyrocyte cultures to evaluate the functional status of IL-17RA. Our data indicates that serum IL-17 levels are significantly increased in intractable GD and affected thyrocytes show functional IL-17R expression. These changes facilitate the IL-17-mediated upregulation of IL-6, CXCL10, and ICAM-1. The IL-17/IL-17R interaction could be a potential target for therapeutic interventions in intractable GD.

Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy

Prostate specific antigen (PSA) is still the best available tumour marker in prostate cancer (PCa), but presents some limits. Therefore, there is a need for novel markers in the detection and management of PCa. The 80-kDa soluble form of E-cadherin (sE-cad) and the cytokine IL-6 are being discussed as supplemental serum markers for PCa. In this study, sE-cad and IL-6 serum levels were determined in patients with pathological localized or locally advanced PCa without any previous treatment. These patients underwent radical retropubic prostatectomy (RRP) in accordance with the EAU Guidelines on Prostate Cancer. The molecules were determined via immunoenzymatic assays in samples collected before and after surgery. Statistical analysis was performed by Student's t-test and Pearson's correlation test. sE-cad levels were 6.0 ± 2.7 and 4.6 ± 2.3 µg/ml, before and after RRP, respectively. A highly statistically significant decrease in sE-cad concentrations after RRP was observed (p<0.0001), in 50/61 patients (82%). sE-cad levels before and after surgery were correlated (Pearson's correlation coefficient, r=0.6993, p<0.0001). sE-cad values detected after surgery were higher in patients with PSA levels >10 ng/ml (p<0.05). sE-cad levels before RRP were significantly higher in patients with G3 tumours compared to those with G2 tumours (p<0.02). Finally, sE-cad concentrations both before and after surgery were higher in tumours with Gleason score =7 compared to those with Gleason score <7 (p<0.002 and p<0.05, respectively). Preliminary data from 20 patients indicated a statistically significant increase in IL-6 levels after RRP (11.2 vs. 7.2 pg/ml, p<0.001). This is the first study on the reduction in sE-cad levels after RRP in PCa patients. Moreover, it shows that preoperative sE-cad concentrations are higher in patients with less differentiated PCa. Promising findings of this pilot study may lead to investigation of sE-cad in a larger study with follow-up.

IL-6 Plays Crucial Roles in Sporadic Colorectal Cancer through the Cytokine Networks including CXCL7

IL-6 is a multifunctional cytokine and involved in variety of carcinogenesis. However, the association between IL-6 and sporadic colorectal cancer has not been fully explained. Here, we investigated the role of IL-6 signaling and the cytokine network in sporadic colorectal cancer. We investigated the serum IL-6 levels in patients with sporadic colorectal adenoma, cancer patients, and normal controls. In addition, the expressions of IL-6, gp130, and the IL-6 receptor subunit were investigated in biopsy specimens collected from these subjects. Furthermore, the expressions of CXCL7 and CXCR2, a chemokine and its receptor involved in IL-6 production, were also investigated. We observed an elevated level of serum IL-6 in colorectal cancer patients and an increased expression of IL-6 in colorectal cancer tissues, compared with the levels in a control group and in patients with adenoma. The phosphorylation of gp130 was also increased in the colorectal cancer tissues, compared with that in control and adenoma tissues. The expressions of CXCL7 and CXCR2 in the colorectal cancer tissues were also higher than those in control and adenoma tissues. IL-6 signaling is involved in sporadic colorectal cancer. In addition, the increased expressions of CXCL7 and CXCR2 might, in turn, increase the expression of IL-6 in colorectal cancer. Further studies are required to elucidate the function of the IL-6 signaling and the cytokine network in sporadic colorectal cancer.

IL-6 Plays Crucial Roles in Sporadic Colorectal Cancer through the Cytokine Networks including CXCL7

IL-6 is a multifunctional cytokine and involved in variety of carcinogenesis. However, the association between IL-6 and sporadic colorectal cancer has not been fully explained. Here, we investigated the role of IL-6 signaling and the cytokine network in sporadic colorectal cancer. We investigated the serum IL-6 levels in patients with sporadic colorectal adenoma, cancer patients, and normal controls. In addition, the expressions of IL-6, gp130, and the IL-6 receptor subunit were investigated in biopsy specimens collected from these subjects. Furthermore, the expressions of CXCL7 and CXCR2, a chemokine and its receptor involved in IL-6 production, were also investigated. We observed an elevated level of serum IL-6 in colorectal cancer patients and an increased expression of IL-6 in colorectal cancer tissues, compared with the levels in a control group and in patients with adenoma. The phosphorylation of gp130 was also increased in the colorectal cancer tissues, compared with that in control and adenoma tissues. The expressions of CXCL7 and CXCR2 in the colorectal cancer tissues were also higher than those in control and adenoma tissues. IL-6 signaling is involved in sporadic colorectal cancer. In addition, the increased expressions of CXCL7 and CXCR2 might, in turn, increase the expression of IL-6 in colorectal cancer. Further studies are required to elucidate the function of the IL-6 signaling and the cytokine network in sporadic colorectal cancer.